DISCLAIMER: SARM's are not intended for human consumption and are not approved by, or otherwise endorsed by the US Food and Drug Administration. The introduction of SARMs has been a recent advancement in performance-enhancing drugs with anabolic effects on the muscle without adverse effects on other tissues. These compounds are currently in various stages of development, and their use is only legal for research purposes at this time. All clinical research must be conducted with oversight from the appropriate Institutional Review Board (IRB). All preclinical research must be conducted with oversight from the appropriate Institutional Animal Care and Use Committee (IACUC) following the guidelines of the Animal Welfare Act (AWA).
Cardarine activates PPAR delta receptors, which are proteins that control important cellular metabolic activities that contribute to energy balance. PPAR delta can also be used to modify muscle fibers and enhance running endurance by reprogramming them. GW has been shown to have a wide range of benefits, but GW was never approved for human use due to obscure toxicology concerns that were never properly validated. Cardarine was found to boost fatty acid usage (as an ergone) in skeletal muscle and protect against diet-induced obesity and type 2 diabetes in rats. It increased good cholesterol levels in overweight monkeys while lowering bad cholesterol levels.
Cardarine was discovered when researchers analyzed data from previous studies of atrial fibrillation and heart failure. The study's findings further solidified the potential value of Cardarine in the treatment of metabolic diseases and cardiovascular disease. It was also hoped that Cardarine might be used to fight hypertension, which costs the United States approximately $50 billion each year in healthcare expenditures according to the CDC, demonstrating there is an obvious need for new treatments to address it. However, despite the promising outlook on this compound, a relatively recent study, "PPARβ/δ a potential target in pulmonary hypertension blighted by cancer risk" published in the journal of Pharmacological Reports, has uncovered the potential carcinogenic effects of GW501516. The literature highlighted warnings that Cardarine was linked (to an unknown degree of tenuousness) to cancer in several rodent studies. GW has also been shown to enhance the growth of tumors and promote metastasis (cancer cells breaking away from a tumor and invading other parts of the body). Cardarine is still being studied for its positive role in combating diabetes, but there are likely more promising PPAR delta agonists waiting on deck that hasn't caused damage nor had their research halted due to GW's history.
While topically, the researchers' cautious behavior and often fearful alarm regarding the literature surrounding GW501516 may seem warranted, the carcinogenic "evidence" proposed thus far suffers integral non-causality-correlated data which subsequently creates a fatalistic criterion of various logical fallacies. There are some concerns that GW could potentially be toxic or harmful when used long-term; however, evidence supporting this view is limited at best. The first signs of toxicity came from unpublished research done by the GW-supplier GSK, which was uncovered by a FOIA. This compound has been associated with a risk of cancer in mice & rats when used long-term; however, the particular rodents in question here (that were researched in one of the notorious studies) had been genetically altered with a cancer gene called v-Ki-ras (which is why they're more likely than other rodents, and presumably humans for that matter, to develop tumors). This genetic alteration effectively promotes somewhat of a predisposition towards developing cancers of many kinds including lung adenocarcinoma — GW did not seem to increase the incidence or accelerate the appearance of malignant cells in any treated rodent subject compared to controls.
FDA DISCLAIMER: SARM's are not intended for human consumption and are not approved by, or otherwise endorsed by the US Food and Drug Administration. The introduction of SARMs has been a recent advancement in performance-enhancing drugs with anabolic effects on the muscle without adverse effects on other tissues. These compounds are currently in various stages of development, and their use is only legal for research purposes at this time.
The only evidence that Cardarine promotes cancer initiation comes from suspicious conference abstracts in which rats were given insanely high doses of Cardarine every day for two years. If the data are accurate, it would provide evidence that Cardarine might cause cancer. However, since this research was never peer-reviewed and published in an academic journal, the rest of the scientific field can't evaluate it objectively. GW501516 does not appear to be carcinogenic at normal doses and even appears to have antitumor activity in animals that do develop tumors while taking it — animal studies show GW actually makes some cancers shrink or disappear completely, so I'm sure you can begin to realize the ambiguity in the black-&-white carcinogenic claims surrounding Cardarine.
The advantages derived from GW were clearly not without promise; by increasing lipid oxidation and decreasing fat mass accumulation, it appeared to be capable of axiomatically reducing obesity. It decreased adipocyte differentiation which prevents new fat cell formation through inhibition of CCAAT/enhancer-binding protein β (C/EBPβ), which can induce insulin resistance in GW subjects. GW also decreased food intake by disrupting neuropeptide Y levels, increasing plasma adiponectin concentrations, and stimulating glucose uptake through an AMPK pathway — all of these are benefits that GW seemed to have on lipid metabolism without any adverse effects, excluding the feasible oncogenic potentialities acknowledged above.
GW501516 works to activate PPAR delta receptors, which can lead to anti-inflammatory effects like decreasing TNF alpha production (a cytokine used in the immune system) as well as increasing insulin sensitivity by reducing oxidative stress — all of which are beneficial for those suffering from diseases such as cancer. GW has been shown to reduce inflammation levels not only in the heart but also throughout other areas affected by chronic inflammatory conditions like arthritis or even psoriasis. GW was also shown to increase mitochondrial mass and strength in skeletal muscle cells, which would promote endurance for athletes seeking performance-enhancing aids (PEDs), though please note, GW501516 (CARDARINE) IS NOT FOR INTENDED HUMAN INGESTION AND IS NOT LEGAL OR APPROVED FOR HUMAN CONSUMPTION AND/OR ADMINISTRATION. These advantageous incontrovertibilities are important not only because it offers great promise as a treatment option but GW may even serve as an effective anti-obesity agent with its ability to activate fat-burning genes. GW also increases enzymes responsible for energy production within mitochondria.
Cardarine was also found effective at inhibiting atherosclerosis formation, improving endothelial function, lowering blood pressure via an angiotensin II receptor blocker called losartan, preventing cardiac hypertrophy, and improving cardiac function in GW users. However, GW wasn't without its faults or limitations — GW is a PPAR delta activator and as such it does not discriminate between the different isoforms of this receptor (it can activate all three). Therefore, GW could potentially induce insulin resistance when used long-term by overstimulating these receptors which are found in tissues other than adipose tissue. GW should be seen as a therapeutic tool for use in the short term (AND NEVER UTILIZED INSIDE OF HUMANS AT ITS CURRENT FDA STATUS), which is why GW501516 has not yet been approved by the FDA for human administration, despite its potential to treat diseases like cancer and obesity.
FDA DISCLAIMER: SARM's are not intended for human consumption and are not approved by, or otherwise endorsed by the US Food and Drug Administration. The introduction of SARMs has been a recent advancement in performance-enhancing drugs with anabolic effects on the muscle without adverse effects on other tissues. These compounds are currently in various stages of development, and their use is only legal for research purposes at this time.
Given the noted data above, paired with our rationale, GW501516 (Cardarine) has the potential to be a game-changer in the fight against obesity and cancer. GW is an amazing tool that can not only reduce body fat but also make our cells more efficient, which will ultimately lead target lab animals to lose weight if they are overweight/obese with excess adipose tissue (fat). GW was found effective at inhibiting atherosclerosis formation, improving endothelial function, lowering blood pressure via an angiotensin II receptor blocker called losartan, preventing cardiac hypertrophy, and improving cardiac function in GW targetted subjects. The associated risks with regard to Cardarine are absolutely worth acknowledging as perceptible (at least in correlated practice) and, as with all research compounds, should be used with maximal caution. GW has the potential to induce insulin resistance when used long-term by overstimulating these receptors, which are found in tissues other than adipose tissue. As we previously covered, GW501516 will also increase enzymes responsible for energy production within mitochondria so GW subjects may experience an increased demand for oxygen consumption because mitochondrial mass increases with GW administration especially in skeletal muscle cells, and as such we anticipate that Cardarine could potentially cause cardiac problems unless the target lab animal is subjected to regular exercise or weight-bearing activity; this should ultimately facilitate the mitigation of these issues arising.
Generally speaking, GW501516 (Cardarine) can & has been illegally abused (by individuals) as a PED with anabolic and ergogenic properties that augment endurance, reduces body fat mass, increases mitochondrial enzymes responsible for energy production within mitochondria (mitochondrial biogenesis), etc. GW501516 (CARDARINE) IS NOT FOR INTENDED HUMAN INGESTION AND IS NOT LEGAL OR APPROVED FOR HUMAN CONSUMPTION AND/OR ADMINISTRATION. GW would appear to be effective in reducing inflammation levels not only in the heart but also throughout other areas affected by chronic inflammatory conditions like arthritis or even psoriasis. GW was found to increase insulin sensitivity by reducing oxidative stress — all of which could be beneficial in the future for patients suffering from diseases such as cancer. GW has been shown to reduce inflammation levels not only in the heart but also throughout other areas affected by chronic inflammatory conditions like arthritis or even psoriasis GW works to activate PPAR delta receptors and its ability to potentially induce insulin resistance when used long-term, supplemented with the appropriate & approved medical execution.
In conclusion, GW501516 has the potential to be an extremely beneficial research compound for scientists around the world. Cardarine has continued to be one of the most popularly used compounds in scientific experimentation, yet is also widely abused among athletes looking to obtain lean muscle mass or improve their athletic performance without actually training harder or longer than they do now (we do NOT endorse nor condone illicit behavior of ANY kind as experimental & unapproved compounds can come with many associated side effects and health risks that are still being studied today at length by various research communities, globally).
GW501516 (Cardarine) is NOT presently considered safe, nor is it legal to administer any unapproved research chemicals to yourself, or any other human.
DISCLAIMER: SARM's are not intended for human consumption and are not approved by, or otherwise endorsed by the US Food and Drug Administration. The introduction of SARMs has been a recent advancement in performance-enhancing drugs with anabolic effects on the muscle without adverse effects on other tissues. These compounds are currently in various stages of development, and their use is only legal for research purposes at this time. All clinical research must be conducted with oversight from the appropriate Institutional Review Board (IRB). All preclinical research must be conducted with oversight from the appropriate Institutional Animal Care and Use Committee (IACUC) following the guidelines of the Animal Welfare Act (AWA).
The MK-2866 selective androgen receptor modulator (GTx-024) selectively targets muscle cells with an affinity of 3.8 nM and exhibits (research suggests) the ability to increase lean body mass, decrease fat deposition, and improve bone density among subjects [§2 - T.O.U.] in good physical condition.
RAD140 is an orally available, non-steroidal [§2 - T.O.U.] SARM that is the subject of ongoing preclinical and clinical studies, designed to artificially augment testosterone [§2 - T.O.U.] (particularly in low-T patients [§2 - T.O.U.]) in an effort to increase androgen-responsive tissues.
LGD-4033 is a potent, selective androgen receptor modulator that has been designed to treat subjects [§2 - T.O.U.] who suffer from muscle wasting diseases by elevating lean muscle mass [§2 - T.O.U.].
GW501516 is a potent PPARβ (peroxisome proliferator-activated receptor) agonist that exhibits 1,000-fold more selectivity than existing subtypes and has been shown to regulate gene expression in lipid catabolism.
